Velan Capital Investment Management LP
13F Reported Value
ⓘ$164.2M
incl. option notional
Equity Holdings
ⓘ$163.2M
Option Notional
ⓘ$999,585
$0 puts / $999,585 calls
Holdings
51
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Velan Capital Investment Management LP disclosed 51 positions worth $164.2M in its Form 13F-HR for Q2 2026 — $163.2M in common stock plus $999,585 of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 18.2% of the equity portfolio, followed by $MPLT and $STRO. During the quarter the fund opened 7 new positions and exited 5 — including a new stake in $CCCC and a full exit from $ESPR. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Velan Capital Investment Management LP’s Form 13F-HR filing with the SEC under CIK 1848809.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- $29.7M88,781 sh
- —
Quality
$17.7M492,893 sh - 15.3#2,855
Quality
$17.0M512,160 sh - —
Quality
$11.2M1,085,000 sh - —
Quality
$10.9M2,844,652 sh - —
Quality
$8.7M65,630 sh - —
Quality
$8.0M549,985 sh - $6.9M700,000 sh
- —
Quality
$6.7M827,500 sh - 14.9
Quality
$6.0M451,255 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $29.7M | 88,781 |
 MapLight Therapeutics, Inc.$MPLT | — | $17.7M | 492,893 |
 SUTRO BIOPHARMA, INC.$STRO | 15.3#2,855 | $17.0M | 512,160 |
 Immix Biopharma, Inc.$IMMX | — | $11.2M | 1,085,000 |
 Protara Therapeutics, Inc.$TARA | — | $10.9M | 2,844,652 |
 Abivax S.A.$ABVX | — | $8.7M | 65,630 |
 TENAX THERAPEUTICS, INC.$TENX | — | $8.0M | 549,985 |
 Anteris Technologies Global Corp.$AVR | — | $6.9M | 700,000 |
 Edesa Biotech, Inc.$EDSA | — | $6.7M | 827,500 |
 Evommune, Inc.$EVMN | 14.9 | $6.0M | 451,255 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Velan Capital Investment Management LP's 51 positions.
Showing top 10 of 51 holdings.
Sector Allocation
Healthcare
$163.2M
Full Holdings — Velan Capital Investment Management LP (Q2 2026)
All 51 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $29.7M | 18.2% | -12% | — |
| 2 | $MPLT | MapLight Therapeutics, Inc. | $17.7M | 10.8% | +0% | — |
| 3 | $STRO | SUTRO BIOPHARMA, INC. | $17.0M | 10.4% | +0% | 15.3 |
| 4 | $IMMX | Immix Biopharma, Inc. | $11.2M | 6.8% | +47% | — |
| 5 | $TARA | Protara Therapeutics, Inc. | $10.9M | 6.7% | +0% | — |
| 6 | $ABVX | Abivax S.A. | $8.7M | 5.4% | -15% | — |
| 7 | $TENX | TENAX THERAPEUTICS, INC. | $8.0M | 4.9% | -6% | — |
| 8 | $AVR | Anteris Technologies Global Corp. | $6.9M | 4.2% | +0% | — |
| 9 | $EDSA | Edesa Biotech, Inc. | $6.7M | 4.1% | +0% | — |
| 10 | $EVMN | Evommune, Inc. | $6.0M | 3.7% | +1% | 14.9 |
| 11 |  $AVTX | Avalo Therapeutics, Inc. | $6.0M | 3.7% | +75% | 11.7 |
| 12 |  $XNCR | Xencor Inc | $4.1M | 2.5% | +2% | 11.6 |
| 13 |  $RZLT | Rezolute, Inc. | $3.9M | 2.4% | +0% | — |
| 14 |  $HRTX | HERON THERAPEUTICS, INC. /DE/ | $3.7M | 2.3% | +0% | 24.7 |
| 15 |  $VRCA | Verrica Pharmaceuticals Inc. | $2.9M | 1.8% | +0% | 32.7 |
| 16 |  $CCCC | C4 Therapeutics, Inc. | $2.7M | 1.6% | NEW | 18.2 |
| 17 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $2.3M | 1.4% | +0% | — |
| 18 |  $ADMA | ADMA BIOLOGICS, INC. | $2.1M | 1.3% | NEW | 69.7 |
| 19 |  $RNTX | Rein Therapeutics, Inc. | $1.8M | 1.1% | NEW | — |
| 20 |  $LYEL | Lyell Immunopharma, Inc. | $1.5M | 0.9% | +3% | 9.3 |
| 21 |  $NSRX | Nasus Pharma Ltd | $1.3M | 0.8% | +0% | — |
| 22 |  $PROF | Profound Medical Corp. | $1.1M | 0.7% | -40% | — |
| 23 |  $JSPR | Jasper Therapeutics, Inc. | $1.1M | 0.7% | +0% | — |
| 24 | $TENXCALL | TENAX THERAPEUTICS, INC. | $999,585 | — | NEW | — |
| 25 |  $PTGX | Protagonist Therapeutics, Inc | $453,546 | 0.3% | +0% | 59.4 |
| 26 |  $CTMX | CytomX Therapeutics, Inc. | $450,000 | 0.3% | -78% | 8.7 |
| 27 |  $NMRA | Neumora Therapeutics, Inc. | $391,000 | 0.2% | +188% | — |
| 28 |  $NRIX | Nurix Therapeutics, Inc. | $388,160 | 0.2% | +0% | 6.4 |
| 29 |  $OVID | Ovid Therapeutics Inc. | $349,700 | 0.2% | -19% | 26.4 |
| 30 |  $DTIL | PRECISION BIOSCIENCES INC | $314,400 | 0.2% | +0% | 10.6 |
| 31 |  $MLYS | Mineralys Therapeutics, Inc. | $296,780 | 0.2% | +0% | — |
| 32 |  $MGNX | MACROGENICS INC | $277,200 | 0.2% | +100% | 39.6 |
| 33 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $243,880 | 0.1% | +0% | — |
| 34 |  $ARTV | Artiva Biotherapeutics, Inc. | $242,500 | 0.1% | +0% | 9.7 |
| 35 |  $REPL | Replimune Group, Inc. | $221,400 | 0.1% | +0% | — |
| 36 |  $SNDX | Syndax Pharmaceuticals Inc | $218,600 | 0.1% | +0% | 33.8 |
| 37 |  $IMNM | Immunome Inc. | $211,900 | 0.1% | +0% | 25.3 |
| 38 |  $TECX | Tectonic Therapeutic, Inc. | $206,250 | 0.1% | NEW | — |
| 39 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $205,200 | 0.1% | -80% | — |
| 40 |  $KPTI | Karyopharm Therapeutics Inc. | $195,400 | 0.1% | +33% | 15.1 |
| 41 |  $ANTX | AN2 Therapeutics, Inc. | $193,600 | 0.1% | NEW | — |
| 42 |  $VRDN | Viridian Therapeutics, Inc.\DE | $183,700 | 0.1% | -89% | 27.2 |
| 43 |  $SCYX | SCYNEXIS INC | $162,800 | 0.1% | NEW | — |
| 44 |  $QNRX | Quoin Pharmaceuticals, Ltd. | $156,680 | 0.1% | -62% | — |
| 45 |  $XLO | Xilio Therapeutics, Inc. | $136,850 | 0.1% | +0% | 35.6 |
| 46 |  $NSPR | InspireMD, Inc. | $103,711 | 0.1% | -93% | — |
| 47 |  $KLRS | Kalaris Therapeutics, Inc. | $101,750 | 0.1% | +39% | — |
| 48 |  $LRMR | Larimar Therapeutics, Inc. | $100,650 | 0.1% | +0% | — |
| 49 |  $PRQR | ProQR Therapeutics N.V. | $83,700 | 0.1% | +0% | — |
| 50 |  $CNTX | Context Therapeutics Inc. | $33,068 | 0.0% | -40% | — |
| 51 |  $GOSS | Gossamer Bio, Inc. | $11,522 | 0.0% | +0% | 8.2 |
New Positions (7)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Velan Capital Investment Management LP including:
Track Velan Capital Investment Management LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Velan Capital Investment Management LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Velan Capital Investment Management LP
13F Pro is an AI hedge fund tracker and stock research platform. For Velan Capital Investment Management LP (SEC CIK: 1848809), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Velan Capital Investment Management LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.